F-star Therapeutics Inc. Common Stock
(NASDAQ:FSTX)
Description
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.
FSTX Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$6.1700 |
Previous Close Volume |
86390 |